Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 17/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 14/20 | 0.49 |
| ▸ | HTR1A | P08908 | 3/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.37 |
| ▸ | HTR1B | P28222 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4305312 | 1.00 | KCNJ1 (0.49) | KCNJ1KCNH2HTR1ADRD2HTR2A | |
| SCHEMBL4306722 | 0.91 | KCNJ1 (0.51) | KCNJ1KCNH2 | |
| SCHEMBL4306725 | 0.91 | KCNJ1 (0.51) | KCNJ1KCNH2 | |
| SCHEMBL4305101 | 0.90 | KCNJ1 (0.50) | KCNJ1KCNH2 | |
| SCHEMBL4305098 | 0.90 | KCNJ1 (0.50) | KCNJ1KCNH2 | |
| SCHEMBL4300904 | 0.90 | KCNJ1 (0.50) | KCNJ1KCNH2 | |
| SCHEMBL4300899 | 0.90 | KCNJ1 (0.50) | KCNJ1KCNH2 | |
| SCHEMBL4316851 | 0.88 | KCNJ1 (0.52) | KCNJ1KCNH2 | |
| SCHEMBL4316855 | 0.88 | KCNJ1 (0.52) | KCNJ1KCNH2 | |
| SCHEMBL13185850 | 0.88 | KCNJ1 (0.46) | KCNJ1KCNH2HTR1ADRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130267497-A1 | KINASE INHIBITORS | ALLERGAN INC (US) | 2013-10-10 | — | — | US | disclosed |
| US-8455656-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20120238558-A9 | Kinase inhibitors | ALLERGAN, INC. | 2012-09-20 | — | — | US | disclosed |
| US-20090286773-A1 | Kinase inhibitors | ALLERGAN, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20060004084-A1 | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267497-A1 | KINASE INHIBITORS | PTK2, MAP3K6, MAP3K20 | KCNJ1 4366/4885KCNH2 3956/4885HTR1A 3359/4885 |
| US-20090286773-A1 | Kinase inhibitors | PTK2, MAP3K6, MAP3K20 | KCNJ1 4366/4885KCNH2 3956/4885HTR1A 3359/4885 |
| US-20060004084-A1 | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | CDK2, ERBB2, MAP3K3 | KCNJ1 3104/4885KCNH2 1780/4885HTR1A 987/4885 |
| US-20120238558-A9 | Kinase inhibitors | PTK2, MAP3K6, MAP3K20 | KCNJ1 4366/4885KCNH2 3956/4885HTR1A 3359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.